TNF and autoimmune hepatitis: As an example, current literature suggests that antibody therapies such as anti‐CD20 or anti‐TNF therapy have only been utilised in <50 patients worldwide with AIH, and even then, only in the context of late disease.45, 46 In contrast, the alternative treatment paradigm should be one of treating early disease aggressively with potential disease modifiers or stoppers, to avoid life‐long therapy with corticosteroids and other drugs that have been proven outdated for the majority of other inflammatory autoimmune disorders.